ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,994.57
-0.76%
Dow Jones
44,421.91
-0.28%
US Dollar vs MXN
20.44454
0.25%
Brent Oil
74.875
-0.64%
Bitcoin
98,694.71
-2.69%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Akebia Therapeutics Inc (AKBA)

  7. Akebia Therapeutics Inc (AKBA) Noticias

Akebia Therapeutics Inc

Akebia Therapeutics Inc (AKBA)

NASDAQ
2.12
-0.12
(-5.36%)
Cerrado 03 Febrero 3:00PM
Delayed by 15 minutes
2.20
0.08
( 3.77% )
Pre Mercado: 3:00AM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

AKBA Noticias

Solo noticias oficiales

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
10 horas hace
AKBA (-5.36%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
10 horas hace
AKBA (-5.36%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
11 horas hace
AKBA (-5.36%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
30 Enero 2025
AKBA (-5.36%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
22 Enero 2025
AKBA (-5.36%)

Form 8-K - Current report
Edgar (US Regulatory)
13 Enero 2025
AKBA (-5.36%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
08 Noviembre 2024
AKBA (-5.36%)

AKBA Discussion

Ver más
TrendTrade2016 TrendTrade2016 2 semanas hace
AKBA test that 2.50 from a year ago
👍️0
TrendTrade2016 TrendTrade2016 2 semanas hace
AKBA breaking out
👍️0
glenn1919 glenn1919 2 semanas hace
AKBA....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 semanas hace
akba........................https://stockcharts.com/h-sc/ui?s=akba&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 semanas hace
AKBA.............................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 semanas hace
AKBA.................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 meses hace
AKBA.....................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 3 meses hace
AKBA BIO BEAST INTO FDA
👍️0
TrendTrade2016 TrendTrade2016 3 meses hace
AKBA BEASTING LONG...FDA APPROVED DRUG COMES TO MARKET IN JAN
👍️0
TrendTrade2016 TrendTrade2016 3 meses hace
AKBA BUILDING 1.79 BREAK IS COMING
👍️0
TrendTrade2016 TrendTrade2016 3 meses hace
AKBA GAPPING AND READY FOR 1.79
👍️0
TrendTrade2016 TrendTrade2016 3 meses hace
AKBA BACK IN PLAY UNTIL JAN 2025...FDA COMING
👍️0
glenn1919 glenn1919 5 meses hace
AKBA.....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 meses hace
AKBA................................https://stockcharts.com/h-sc/ui?s=ARKB&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 meses hace
AKBA......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 meses hace
AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Krspecialized Krspecialized 7 meses hace
I believe the current news releases may have answered your question. GLTA
👍️0
Toofuzzy Toofuzzy 8 meses hace
Why do you say we have a gold mine here ?

Toofuzzy
👍️0
Krspecialized Krspecialized 8 meses hace
There's no doubt we have a gold mine here, and at some point it will be load up time. Figuring out when is the big question!
👍️0
eyeownu eyeownu 8 meses hace
SCARY MOVIE
👍️0
eyeownu eyeownu 9 meses hace
https://journey.ct.events/view/a825b116-e5ee-4e76-ad8d-2e9e9116aa21 tomorrows web cast
👍️0
eyeownu eyeownu 9 meses hace
added 2k@ 1.11
👍️ 1
glenn1919 glenn1919 9 meses hace
AKBA................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 meses hace
AKBA under $2

👍️0
eyeownu eyeownu 10 meses hace
ask is stacked! someone needs to slap it.
👍️0
eyeownu eyeownu 10 meses hace
$AKBA RELOAD
👍️0
Firestorm22 Firestorm22 10 meses hace
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
Firestorm22 Firestorm22 10 meses hace
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
ErnieBilco ErnieBilco 10 meses hace
I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes
👍️ 1
Firestorm22 Firestorm22 10 meses hace
Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.
👍️ 1
ErnieBilco ErnieBilco 10 meses hace
Classic sell the news. Probable offering coming next week to dilute on the good news.
👍️0
Firestorm22 Firestorm22 10 meses hace
Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??
👍️0
Krspecialized Krspecialized 10 meses hace
Long solid position here!
👍️0
Limey42 Limey42 10 meses hace
Long term play. Congrats all!
👍️ 1
dugie100 dugie100 10 meses hace
Something didn’t look good , I guess!
👍️0
TrendTrade2016 TrendTrade2016 10 meses hace
AKBA should see 3 bucks
👍️0
TrendTrade2016 TrendTrade2016 10 meses hace
AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!
👍️0
glenn1919 glenn1919 10 meses hace
AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 meses hace
AKBA new 52 hi
👍️0
eyeownu eyeownu 10 meses hace
$AKBA looking good damn! she fine.
👍️ 1
glenn1919 glenn1919 11 meses hace
AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 11 meses hace
$AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA
👍️ 1
Monksdream Monksdream 11 meses hace
AKBA 10Q March 4
👍️0
Tyrus603 Tyrus603 11 meses hace
Excellent chart. Thank you for posting.

Found myself studying it for quite a bit.

As it really is a dream chart for both swing traders AND long term buy & hold investors alike.
👍️0
glenn1919 glenn1919 11 meses hace
AKBA..............................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 11 meses hace
$AKBA
👍️0
eyeownu eyeownu 11 meses hace
$AKBA reversal incoming?
👍️0
eyeownu eyeownu 1 año hace
CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

At the closing, Akebia drew the first tranche of $37.0 million and used the proceeds to pay down $35.0 million of principal outstanding from a loan agreement with Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit funds, plus interest and fees. The new agreement substantially extends the interest-only period in the event of vadadustat approval by the U.S. Food and Drug Administration (FDA) without requiring any principal repayment until December 31, 2025, with an option for Akebia to extend until December 31, 2026.
👍️0
eyeownu eyeownu 1 año hace
$AKBA profit taking! hope you took some off the table!
👍️0
eyeownu eyeownu 1 año hace
PDUFA explanation https://www.fool.com/terms/p/pdufa-date/

What percentage of PDUFA are approved?
Characteristic Percentage of drugs approved in 2023
Met PDUFA goal date* 89%
First cycle of review 84%
Approved in the United States before receiving approval in any other country 64%
Priority review 56%

From
👍️0

Su Consulta Reciente

NASDAQ
AKBA
Akebia Therapeutics
NYSE
PHG
Koninklijke Philips NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios